Review of Tumor Suppressor Gene P53
Abstract
Background: During tumorigenesis, cells proliferate unchecked, altering tissue homeostasis and leading to subsequent hyperplasia. This process parallels the recovery of cell cycle, abnormal DNA repair, and the passivation of apoptotic programs in response to DNA damage. In most human cancers, these processes are associated with dysfunctions of the tumor suppressor p53. As a key transcription factor, the evolutionarily conserved tumor suppressor p53 (encoded by TP53) plays a central role in response to various cellular stresses. A variety of biological processes are regulated by p53 such as cell cycle arrest, apoptosis, senescence and metabolism. Besides these well-known roles of p53, accumulating evidence show that p53 also regulates innate immune and adaptive immune responses. p53 influences the innate immune system by secreted factors that modulate macrophage function to suppress tumourigenesis. Dysfunction of p53 in cancer affects the activity and recruitment of T and myeloid cells, resulting in immune evasion. p53 can also activate key regulators in immune signaling pathways which support or impede tumor development[1]. Hence, it seems that the tumor suppressor p53 exerts its tumor suppressive effect to a considerable extent by modulating the immune response. In this review, we concisely discuss the emerging connections between p53 and immune responses, and their impact on tumor progression. Understanding the role of p53 in regulation of immunity will help to developing more effective anti-tumor immunotherapies for patients with TP53 mutation or depletion.
References
[2] Levine AJ., Oren M. (2009). The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9 749–758.
[3] Hanahan D., Weinberg R. A. (2011). Hallmarks of cancer: the next generation. Cell 144 646–674.
[4] Watanabe M., Moon K. D., Vacchio M. S., Hathcock K. S., Hodes R. J. (2014). Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity 40 681–691.
[5] Blagih J., Zani F., Chakravarty P., Hennequart M., Pilley S., Hobor S., et al. (2020b). Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep. 30 481–496 e486.
[6] Cooks T., Harris C. C., Oren M. (2014). Caught in the cross fire: p53 in inflammation. Carcinogenesis 35 1680–1690.
[7] Trinchieri G. (2012). Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30 677–706.
[8] Niu G., Wright K. L., Ma Y., Wright G. M., Huang M., Irby R., et al. (2005). Role of Stat3 in regulating p53 expression and function. Mol. Cell Biol. 25 7432–7440.
[9] Nijman H. W., Lambeck A., van der Burg S. H., van der Zee A. G., Daemen T. (2005). Immunologic aspect of ovarian cancer and p53 as tumor antigen. J. Transl. Med. 3:34.
[10] Humar M., Azemar M., Maurer M., Groner B. (2014). Adaptive resistance to immunotherapy directed against p53 can be overcome by global expression of tumor-antigens in dendritic cells. Front. Oncol. 4:270.
[11] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57–70.
[12] Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352(6333):345–347.
[13] Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006;10(6):501–514.
[14] Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999;285(5434):1733–1737.
Copyright (c) 2023 Xin Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
